Consensus Genmab A/S Börse Stuttgart

Equities

GE91

US3723032062

Market Closed - Börse Stuttgart Other stock markets 07:29:22 2024-06-17 am EDT			5-day change	1st Jan Change
24 ^EUR	-2.44%		-6.25%	-16.67%

Jun. 10	Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
Jun. 04	Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	MT

Evolution of the average Target Price on Genmab A/S

Price target over the last 5 years

History of analyst recommendation changes

74965d728ec.KqImb1mr0ff1hVBQynfBeiT0d-LKlPeB0gZdKFIL7JU.eJZVPSztk62nsz4y_zCgNFWeNqGP4q_MtnY3ZyA739ps_X8jNduCw8TRAQ~f4b69170d418c5bc34fa6dd93f150b45

Analyst Recommendations on Genmab A/S

Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	Jun. 04	MT
GENMAB : A good start to 2024; guidance unchanged	May. 03
GENMAB : Genmab is available at a bargain price	Mar. 04
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46	Feb. 23	MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating	Feb. 21	MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks	Feb. 15
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating	Jan. 29	MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating	Nov. 09	MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating	Nov. 08	MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded	Nov. 08
GENMAB : Factoring in some caution	23-10-31
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating	23-10-13	MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact	23-08-25
BTIG Starts Genmab at Buy With $44 Price Target	23-08-24	MT
GENMAB : A good Q2 + improved sales guidance	23-08-04
AbbVie, Genmab Say Phase 1/2 Trial of Epcoritamab in Follicular Lymphoma Patients Showed 82% of Overall Response Rate	23-06-28	MT
Genmab Says Epcoritamab Drug Combination Shows 98% Overall Response Rate in Phase 1/2 Trial in Follicular Lymphoma	23-06-09	MT
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating	23-05-22	MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	23-05-16	MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss	23-05-11
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry	23-03-20
HC Wainwright Adjusts Price Target on Genmab to $46 From $51, Maintains Buy Rating	23-03-02	MT
Morgan Stanley Trims Price Target on Genmab to $33 From $34, Maintains Underweight Rating	23-03-01	MT
GENMAB : Promising 2022; even softer 2023 guidance isn’t a worry	23-02-23
Morgan Stanley Adjusts Price Target on Genmab to $34 From $35, Keeps Underweight Rating	23-02-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,800 DKK

Average target price

2,464 DKK

Spread / Average Target

+36.93%

High Price Target

3,000 DKK

Spread / Highest target

+66.71%

Low Price Target

1,600 DKK

Spread / Lowest Target

-11.09%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genmab A/S

Truist Securities
alphavalue	Anas Patel
BMO Capital
RBC Capital Markets
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
William Blair & Co.
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar